Methicillin-Resistant Staphylococcus aureus Infections in Patients With Renal Disorders: A Review
| Autor: | Venkata Raju, Ravindra Nikalji, Sunil Jawale, Jaishid Ahdal, Haresh Patel, Rishi Jain, Kailash N Singh |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Teicoplanin business.industry medicine.drug_class Antibiotics Tigecycline biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease_cause Methicillin-resistant Staphylococcus aureus chemistry.chemical_compound chemistry Internal medicine Linezolid medicine Vancomycin Daptomycin business medicine.drug Antibacterial agent |
| Zdroj: | World Journal of Nephrology and Urology. 8:8-13 |
| ISSN: | 1927-1247 1927-1239 |
| DOI: | 10.14740/wjnu384 |
| Popis: | Methicillin-resistant Staphylococcus aureus (MRSA) infection is a rapidly escalating global health burden. It is not only restricted to patients in the hospital settings but has also rooted deeply in the community settings. With increasing prevalence of life style and kidney diseases, the prevalence of MRSA infections is also expected to rise. MRSA infection plays a major role in renal disorders due to its direct vascular access (VA) thereby making patients undergoing dialysis and renal transplant more vulnerable to infections. Prolonged hospital stay, close proximity to MRSA-infected individual, exposure to broad-spectrum antibiotics, surgery and presence of foreign bodies such as central venous catheters predispose an individual to MRSA infection. Current panel of antibiotic treatment includes vancomycin, teicoplanin, linezolid, daptomycin, tigecycline and ceftaroline. However, emergence of resistant strains and several undesirable features pertaining to safety and tolerability of these drugs have led to limited options available for the management of multidrug-resistant MRSA infection in patients with renal disorders. Therefore, there is an increasing need for developing a new potent antibacterial agent with established renal safety that decreases the mortality and morbidity rates in MRSA-infected renal patients. World J Nephrol Urol. 2019;8(1):8-13 doi: https://doi.org/10.14740/wjnu384 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|